Trial intelligence / Profile preview

Phase III Docetaxel Continuous vs Intermittent Therapy in Hormone-Refractory Prostate Cancer

2005-001602-76Phase 3Completed

Sponsor: Charité – Universitätsmedizin Berlin
Start: Jan 2006
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: 1-year survival rate and Progression of the disease under treatment. Started Jan 2006; status: completed.

Drugs

docetaxel

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2005-001602-76.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-001602-76.